You just read:

Orion Biotechnology Announces Receipt of Pre-IND Guidance From the United States FDA on the Further Development of OB-002O as a Potential Treatment for Solid Tumors

News provided by

Orion Biotechnology Canada

Jun 10, 2019, 11:11 ET